Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved annual flu shot when tested in adults aged 50 years and older in a late-stage ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines.

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

“ [These] strong phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in ...

" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" data-type="post" data-object_id="334655" class="cbxwpbkmarktrig ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of selling combination vaccines. The shot’s efficacy was 27 percent ...